BioLineRx Limited

Just in for biotech podcast listeners!  Ep. 2 of the three-part @BioPharmaDive Power of Persistence podcast series dropped. $BLRX president Holly May discusses building the right team at the right time with dynamic leaders described as "Swiss army knives". bit.ly/4en75oA

Cancer changes not only the life of the person diagnosed, but those who love them. This #NationalFamilyCaregiversMonth, we celebrate the vital role of care partners who inspire us in our work. Meet Jan: #stem-cell-story-collection" target="_blank" rel="nofollow noopener">mobilizationmatters.com/#stem-cell-sto… #NFCMonth

@BioLineRx_Ltd Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at #ASH24. Read Release: prnewswire.com/news-releases/…

#ICYMI: We encourage you to learn more about the recent launch of our new digital patient resource, Mobilization Matters, as well as the patient survey we are conducting in partnership with @HealthTree: ir.biolinerx.com/news-releases/…

People living with multiple myeloma are often asked: “How were you first diagnosed?” Connecting with others to learn from, and share, experiences can help with navigating the path ahead. Find a community around multiple myeloma here: healthtree.org/myeloma/connect

(2/2) We honor the achievements of researchers and organizations dedicated to improving the lives of people living with this condition.

Join us this September for Sickle Cell Awareness Month. Sickle cell disease is a genetic condition that affects red blood cells and is the most common inherited blood disorder in the United States, affecting millions of people worldwide. (1/2)

Last week, we launched Mobilization Matters, a digital resource for multiple myeloma patients preparing for stem cell collection before ASCT, featuring patient stories and educational tools to support patients and caregivers. Learn more: mobilizationmatters.com

Please join us today in recognition of World #Cancer #Research Day! We're committed to contributing to the vision of a cancer free world and to developing life-changing therapies designed to deliver meaningful therapeutic benefits to patients with cancers and rare diseases.

This Apheresis Awareness Day, we’re thrilled to launch Mobilization Matters, a digital resource for multiple myeloma patients preparing for stem cell collection before ASCT. Explore patient stories, tools, and more at mobilizationmatters.com.

Join us this Sept for #Blood #Cancer Awareness Month to continue ongoing efforts in spreading awareness & recognition of multiple myeloma as the 2nd most common type of blood cancer. BioLineRx is committed to advancing care & treatment options with the #multiplemyeloma community.

Multiple myeloma can introduce many “unknowns” including around treatment. If you or a loved one may be undergoing stem cell collection in preparation for autologous stem cell transplant (ASCT), learning more about the process can help: healthtree.org/myeloma/commun…

This September, and every day, we are thankful to work with and serve patients living with #multiplemyeloma, the 2nd most-common hematologic malignancy. What are you thankful for this #bloodcancer awareness month?

This week, BioLineRx’s CEO Phil Serlin discusses how to navigate the delicate balance between launching a company’s first commercial product while also nurturing a robust pipeline and forming collaborations to accelerate growth and maximize impact. biopharmadive.com/spons/podcast-… (2/2)

Join BioLineRx $BLRX for the final episode in the “Power of Persistence” BioPharma Dive podcast series. biopharmadive.com/spons/podcast-… (1/2)

So excited to launch 3-part @BioPharmaDive podcast series: "The Power of Persistence: From Biotech Incubator to Product Launch." In Ep1, Philip Serlin, CEO, shares BioLineRx's journey from incubator to strategic, commercial company. A must-listen! biopharmadive.com/spons/podcast-…

BioLineRx announces multi-center Ph1 clinical trial sponsored by @StJudeResearch to evaluate single agent motixafortide for the mobilization of CD34+ hematopoietic stem cells used in the development of gene therapies for patients with sickle cell disease bit.ly/3wYmHy5

BiolineRx is excited to announce acceptance of an abstract & poster session at #ASCO2024. Dr. Gulam Manji MD PhD, will be presenting on the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial in first-line pancreatic cancer. bit.ly/3Ve1GJe

Published today in @PharmaVoice: We’re excited to share the powerful journey @BioLineRx_Ltd ($BLRX) has taken since its founding, from incubator to publicly-traded commercial company. Enjoy this look back and a brief view of our vision for the future: pharmavoice.com/spons/flipping…

We hope that effective treatments will be continually developed to fight this devastating disease through ongoing research and hard work. (2/2)